Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Merck
Moodys
Baxter

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR KOSELUGO


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Koselugo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00551070 ↗ Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Completed NRG Oncology Phase 2 2007-12-17 This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00551070 ↗ Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Completed National Cancer Institute (NCI) Phase 2 2007-12-17 This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01364051 ↗ Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Active, not recruiting National Cancer Institute (NCI) Phase 1 2011-05-25 This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib sulfate in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.
NCT02839720 ↗ Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Recruiting National Cancer Institute (NCI) Phase 2 2017-04-11 This pilot phase II trial studies how well selumetinib works in treating patients with neurofibromatosis type 1 and cutaneous neurofibromas. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT03155620 ↗ Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting National Cancer Institute (NCI) Phase 2 2017-07-24 This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Koselugo

Condition Name

Condition Name for Koselugo
Intervention Trials
Advanced Malignant Solid Neoplasm 3
Refractory Malignant Solid Neoplasm 3
Low Grade Glioma 3
Refractory Primary Central Nervous System Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Koselugo
Intervention Trials
Glioma 4
Neoplasms 4
Neurofibroma 3
Neurofibromatosis 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Koselugo

Trials by Country

Trials by Country for Koselugo
Location Trials
United States 226
Puerto Rico 4
Canada 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Koselugo
Location Trials
Texas 7
Maryland 7
Maine 6
Florida 6
Alabama 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Koselugo

Clinical Trial Phase

Clinical Trial Phase for Koselugo
Clinical Trial Phase Trials
Phase 3 3
Phase 2 6
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Koselugo
Clinical Trial Phase Trials
Recruiting 6
Active, not recruiting 2
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Koselugo

Sponsor Name

Sponsor Name for Koselugo
Sponsor Trials
National Cancer Institute (NCI) 10
NRG Oncology 1
Merck Sharp & Dohme Corp. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Koselugo
Sponsor Trials
NIH 10
Industry 2
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Moodys
Colorcon
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.